Objective: This study aimed to describe the urodynamic characteristics of post-transplant kidney patients with LUTS who were indicated for urodynamics. Material & Methods: This research is a cross-sectional study conducted at Cipto Mangunkusumo General Hospital between 2011-2017. Data were collected from patients who had undergone urodynamic examination after kidney transplantation due to LUTS/urinary retention. Data were collected from the patient’s medical record. Results: A total of 536 patients underwent kidney transplants at Cipto Mangunkusumo General Hospital from 2011-2017. Eleven patients (2%) developed LUTS and then underwent urodynamic examination with an average age of 41.4 (30.1 ± 52.6) years. Six patients (55%) had type 2 diabetes mellitus (DM) and 5 patients (45%) had hypertension (HT). A total of 6 out of 11 patients (54%) experienced urinary retention of which 4 subjects (67%) had decreased bladder compliance, 4 (67%) patients experienced detrusor overactivity (DO), 3 patients (50%) had bladder outlet obstruction (BOO), while 2 patients (33%) experienced detrusor underactivity (DU) respectively. Of 5 patients without urinary retention, decreased bladder compliance was found in 1 patient (20%), DO in 2 patients (40%), BOO in 1 patient (20%), and no subject experienced DU. In both groups, no subject was discovered to experience any urinary incontinence. Conclusion: Small number of post renal transplantation patients developed LUTS and half of which accompanied by urinary retention. Among these patients, urodynamic examination revealed detrusor overactivity as the most common underlying problem followed by decreased bladder compliance, BOO, and detrusor underactivity
urine retention, kidney transplant, urodynamic profile
Griva K, Davenport A, Newman SP. Health-related quality of life and longterm survival and graft failure in kidney transplantation: a 12-year follow up study. Transplantation, 2013; 95: 740–49.
Dew MA, Switzer GE, Goycoolea JM et al. Does transplantation produce quality of life benefits? A quantitative analysis of the literature. Transplantation, 1997; 64: 1261–73.
Dobbels F, De Bleser L, De Geest S, Fine RN. Quality of life after kidney transplantation: the bright side of life? Adv Chronic Kidney Dis, 2007; 14: 370–78.
Serrano DP, Flechner SM, Modlin CS, Wyner LM, Novick AC. Transplantation into the long-term defunctionalized bladder. J Urol 1996; 156: 885–8.
Bemelmans BL, Meuleman EJ, Frederiks CM. Lower urinary tract symptoms after transplantation. J Urol 2001; 166: 1237– 41.
Silva DM, Prudente AC, Mazzali M et al. Bladder function evaluation before renal transplantation in nonurologic disease: is it necessary? Urology, 2014; 83: 406–10.
Oborn H, Herthelius M: Lower urinary tract symptoms in children and adolescents with chronic renal failure. J Urol, 2010; 183: 312–16.
Tsaur I, Jones J, Melamed RJ et al. Postoperative voiding dysfunction in older male renal transplant recipients. Transplant Proc, 2009; 41: 1615–18.
Mitsui T, Shimoda N, Morita K et al. Lower urinary tract symptoms and their impact on quality of life after successful renal transplantation. Int J Urol, 2009; 16: 388–92.
Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease. BJU Int, 2011; 107: 702–13.
Zermann DH, Janitzky A, Hohne M, Schubert J. Frequency and nocturia after successful renal transplantation: a normal situation? BJU Int, 2006; 97: 555–58.
Chen JL, Lee MC, Kuo HC. Reduction of cystometric bladder capacity and bladder compliance with time in patients with end-stage renal disease. J Formos Med Assoc, 2012; 111: 209–13.
Zermann DH, Loffler U, Reichelt O et al. Bladder dysfunction and end stage renal disease. Int Urol Nephrol, 2003; 35: 93–97.
Mitsui T, Kakizaki H, Kobayashi S et al. Vesicourethral function in diabetic patients: association of abnormal nerve conduction velocity with vesicourethral dysfunction. Neurourol Urodyn, 1999; 18: 639–45
Sarma AV, Jaffe CA, Schottenfeld D, Dunn R, Montie JE, Cooney KA, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among black men. Urology 2002; 59: 362–7.
Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52: 98–105.
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599–604.
Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151–8.
Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, Talamini R, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes (Lond) 2005; 29: 798–803.
Hong J, Kwon S, Yoon H, Lee H, Lee B, Kim HH, et al. Risk factors for benign prostatic hyperplasia in South Korean men. Urol Int 2006; 76: 11–19.
Errando C, Batista JE, Caparros J, Vicente J, Arano P. Urodynamic evaluation and management prior to renal transplantation. Eur Urol 2000; 38: 415–8.